Glutamatergic medications for the treatment of drug and behavioral addictions

Pharmacology Biochemistry and Behavior

Volumn 100, Issue 4, 2012, Pages 801-810

  Olive, M Foster ^a   Cleva, Richard M ^a   Kalivas, Peter W ^b   Malcolm, Robert J ^b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Behavioral addiction; Drug addiction; Glutamate; Pathological gambling; Pharmacological therapy; Substance abuse

Indexed keywords

ACAMPROSATE; ACETYLCYSTEINE; CYCLOSERINE; DIZOCILPINE; DRUGS USED IN THE TREATMENT OF ADDICTION; GABAPENTIN; GLUTAMATE RECEPTOR; GLUTAMIC ACID; LAMOTRIGINE; LORAZEPAM; MEMANTINE; MODAFINIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALTREXONE; PARACETAMOL; PLACEBO; SPERMIDINE; TOPIRAMATE;

ADDICTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CANNABIS ADDICTION; CLINICAL TRIAL (TOPIC); COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG ACTIVITY; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG OVERDOSE; HEROIN DEPENDENCE; HUMAN; INHALANT ABUSE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NARCOLEPSY; NEUROTRANSMISSION; NONHUMAN; OPIATE ADDICTION; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; RELAPSE; REVIEW; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; TOBACCO DEPENDENCE; TRICHOTILLOMANIA; WITHDRAWAL SYNDROME;

ANIMALS; GLUTAMIC ACID; HUMANS; MENTAL DISORDERS; SUBSTANCE-RELATED DISORDERS;

EID: 84855534956     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2011.04.015     Document Type: Review

References (203)

1. Ahmad S, Fowler LJ, Whitton PS. Effects of acute and chronic lamotrigine treatment on basal and stimulated extracellular amino acids in the hippocampus of freely moving rats. Brain Res 2004;1029:41-7. (Pubitemid 39463305)
2. Akhondzadeh S, Hampa AD. Topiramate prevents ecstasy consumption: a case report. Fundam Clin Pharmacol 2005;19:601-2.
3. al Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res 1998;22:810-4. (Pubitemid 28292463)
4. Amen SL, Piacentine LB, Ahmad ME, Li S-J, Mantsch JR, Risinger RC, et al. Repeated Nacetylcysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans. Neuropsychopharmacology 2011;36:871-8.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. 4th, Text Revision ed. Washington DC: American Psychiatric Press; 2002.
6. Andersen ML, Kessler E, Murnane KS, McClung JC, Tufik S, Howell LL. Dopamine transporter-related effects of modafinil in rhesus monkeys. Psychopharmacology 2010;210:439-48.
7. Anderson N, Oliver MN. Oral topiramate effective for alcoholism. J Fam Pract 2003;52:682-3.
8. Anderson AL, Reid MS, Li SH, Holmes T, Shemanski L, Slee A, et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 2009;104:133-9.
9. Anthenelli RM, Blom TJ, McElroy SL, Keck Jr PE. Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. Addiction 2008;103:687-94. (Pubitemid 351389286)
10. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence - the COMBINE study: a randomized controlled trial. JAMA 2006;295:2003-17. (Pubitemid 44794003)
11. Arbaizar B, Gomez-Acebo I, Llorca J. Decrease in tobacco consumption after treatment with topiramate and aripiprazole: a case report. J Med Case Reports 2008;2:198.
12. Arias AJ, Feinn R, Covault J, Kranzler HR. Memantine for alcohol dependence: an open-label pilot study. Addict Disord Their Treat 2007;6:77-83. (Pubitemid 46871891)
13. Baker DA, Xi ZX, Shen H, Swanson CJ, Kalivas PW. The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci 2002;22:9134-41. (Pubitemid 35379084)
14. Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S, et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci 2003;6:743-9. (Pubitemid 36792890)
15. Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 2006;67:554-66. (Pubitemid 43764232)
16. Baltieri DA, Daro FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008;103:2035-44.
17. Berger SP, Winhusen TM, Somoza EC, Harrer JM, Mezinskis JP, Leiderman DB, et al. A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction 2005;100(Suppl 1):58-67. (Pubitemid 40363425)
18. Berk M, Jeavons S, Dean OM, Dodd S, Moss K, Gama CS, et al. Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting. CNS Spectr 2009;14:357-60.
19. Berton F, Francesconi WG, Madamba SG, Zieglgänsberger W, Siggins GR. Acamprosate enhances N-methyl-D-apartate receptor-mediated neurotransmission but inhibits presynaptic GABAB receptors in nucleus accumbens neurons. Alcohol Clin Exp Res 1998;22:183-91. (Pubitemid 28139215)
20. Bird MK, Lawrence AJ. Group I metabotropic glutamate receptors: involvement in drug-seeking and drug-induced plasticity. Curr Mol Pharmacol 2009;2:83-94.
21. Bisaga A, Evans SM. Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology 2004;172:16-24. (Pubitemid 38299746)
22. Bisaga A, Evans SM. The acute effects of gabapentin in combination with alcohol in heavy drinkers. Drug Alcohol Depend 2006;83:25-32.
23. Bisaga A, Comer SD, Ward AS, Popik P, Kleber HD, Fischman MW. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology 2001;157:1-10. (Pubitemid 32758953)
24. Bisaga A, Aharonovich E, Garawi F, Levin FR, Rubin E, Raby WN, et al. A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend 2006;81:267-74. (Pubitemid 43152453)
25. Bonnet U, Banger M, Leweke FM, Maschke M, Kowalski T, Gastpar M. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry 1999;32:107-9. (Pubitemid 29364444)
26. Botreau F, Paolone G, Stewart J. d-Cycloserine facilitates extinction of a cocaine-induced conditioned place preference. Behav Brain Res 2006;172:173-8. (Pubitemid 44037823)
27. Bowers MS, Chen BT, Chou JK, Osborne MPH, Gass JT, See RE, et al. Acamprosate attenuates cocaine and cue-induced reinstatement of cocaine-seeking behavior in rats. Psychopharmacology 2007;195:397-406. (Pubitemid 350160268)
28. Bowers MS, Chen BT, Bonci A. AMPA receptor synaptic plasticity induced by psychostimulants: the past, present, and therapeutic future. Neuron 2010;67:11-24.
29. Bozikas V, Petrikis P, Gamvrula K, Savvidou I, Karavatos A. Treatment of alcohol withdrawal with gabapentin. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:197-9. (Pubitemid 34045168)
30. Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res 2008;32:1429-38.
31. Brown ES, Nejtek VA, Perantie DC, Orsulak PJ, Bobadilla L. Lamotrigine in patients with bipolar disorder and cocaine dependence. J Clin Psychiatry 2003;64:197-201. (Pubitemid 36268323)
32. Brown ES, Perantie DC, Dhanani N, Beard L, Orsulak P, Rush AJ. Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study. J Affect Disord 2006;93:219-22. (Pubitemid 43816049)
33. Cartwright WS. Economic costs of drug abuse: financial, cost of illness, and services. J Subst Abuse Treat 2008;34:224-33. (Pubitemid 351163517)
34. Coderre TJ, Kumar N, Lefebvre CD, Yu JS. A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. J Neurochem 2007;100:1289-99.
35. Collins ED, Ward AS, McDowell DM, Foltin RW, Fischman MW. The effects of memantine on the subjective, reinforcing and cardiovascular effects of cocaine in humans. Behav Pharmacol 1998;9:587-98. (Pubitemid 28552552)
36. Collins ED, Vosberg SK, Ward AS, Haney M, Foltin RW. The effects of acute pretreatment with high-dose memantine on the cardiovascular and behavioral effects of cocaine in humans. Exp Clin Psychopharmacol 2007;15:228-37. (Pubitemid 47445251)
37. Comer SD, Sullivan MA. Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers. Psychopharmacology 2007;193:235-45. (Pubitemid 47025023)
38. Cunningham MO, Jones RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 2000;39:2139-46. (Pubitemid 30645637)
39. Cunningham MO, Woodhall GL, Thompson SE, Dooley DJ, Jones RS. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci 2004;20:1566-76. (Pubitemid 39294695)
40. Dackis CA, Lynch KG, Yu E, Samaha FF, Kampman KM, Cornish JW, et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 2003;70:29-37. (Pubitemid 36385151)
41. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005;30:205-11. (Pubitemid 40024415)
42. Dannon PN, Lowengrub K, Musin E, Gonopolsky Y, Kotler M. 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study. J Clin Psychopharmacol 2007;27:620-4. (Pubitemid 351339450)
43. Davis M, Ressler K, Rothbaum BO, Richardson R. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry 2006;60:369-75. (Pubitemid 44215855)
44. De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate : elucidating the mechanism of action. CNS Drugs 2005;19:517-37. (Pubitemid 41058377)
45. Dickenson AH, Ghandehari J. Anti-convulsants and anti-depressants. Handb Exp Pharmacol 2007:145-77.
46. Donovan JL, DeVane CL, Malcolm RJ, Mojsiak J, Chiang CN, Elkashef A, et al. Modafinil influences the pharmacokinetics of intravenous cocaine in healthy cocainedependent volunteers. Clin Pharmacokinet 2005;44:753-65. (Pubitemid 40994083)
47. Donovan DM, Anton RF, Miller WR, Longabaugh R, Hosking JD, Youngblood M. Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes. J Stud Alcohol Drugs 2008;69:5-13.
48. +-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000;280:107-10.
49. Eroglu C, Allen NJ, Susman MW, O'Rourke NA, Park CY, Ozkan E, et al. Gabapentin receptor α2δ-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 2009;139:380-92.
50. Evans SM, Levin FR, Brooks DJ, Garawi F. A pilot double-blind treatment trial of memantine for alcohol dependence. Alcohol Clin Exp Res 2007;31:775-82. (Pubitemid 46587657)
51. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert F, Fuxe K. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport 1997;8:2883-7. (Pubitemid 27394812)
52. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci Lett 1998;253:135-8. (Pubitemid 28430641)
53. Ferraro L, Antonelli T, Tanganelli S, O'Connor WT, Perez de la Mora M, Mendez-Franco J, et al. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology 1999;20:346-56. (Pubitemid 29099765)
54. 2+ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br J Pharmacol 2000;130:900-6.
55. 2nd, Newton TF. A case report of topiramate in the treatment of nonparaphilic sexual addiction. J Clin Psychopharmacol 2005;25:512-4.
56. Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007;68:1691-700. (Pubitemid 350247498)
57. Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 2008;75:218-65. (Pubitemid 350235390)
58. Gerrard P, Malcolm R. Mechanisms of modafinil: a review of current research. Neuropsychiatr Dis Treat 2007;3:349-64. (Pubitemid 47215010)
59. Gilson AM, Kreis PG. The burden of the nonmedical use of prescription opioid analgesics. Pain Med 2009;10(Suppl 2):S89-S100.
60. Gonzalez G, Desai R, Sofuoglu M, Poling J, Oliveto A, Gonsai K, et al. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend 2007;87:1-9. (Pubitemid 46074378)
61. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007;62:652-7. (Pubitemid 47314380)
62. Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2009;66:756-63.
63. Grant JE, Chamberlain SR, Odlaug BL, Potenza MN, Kim SW. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology 2010a;212:603-12.
64. Grant JE, Potenza MN, Weinstein A, Gorelick DA. Introduction to behavioral addictions. Am J Drug Alcohol Abuse 2010b;36:233-41.
65. Gray KM, Watson NL, Carpenter MJ, Larowe SD. N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study. Am J Addict 2010;19:187-9.
66. Gryder DS, Rogawski MA. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci 2003;23:7069-74. (Pubitemid 36975871)
67. Haney M, Hart C, Collins ED, Foltin RW. Smoked cocaine discrimination in humans: effects of gabapentin. Drug Alcohol Depend 2005;80:53-61. (Pubitemid 41266962)
68. Harris BR, Prendergast MA, Gibson DA, Rogers DT, Blanchard JA, Holley RC, et al. Acamprosate inhibits the binding of neurotoxic effects on trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 2002;26:1779-93. (Pubitemid 36008614)
69. Heinzerling KG, Shoptaw S, Peck JA, Yang X, Liu J, Roll J, et al. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend 2006;85:177-84. (Pubitemid 44666282)
70. Jackson A, Nesic J, Groombridge C, Clowry O, Rusted J, Duka T. Differential involvement of glutamatergic mechanisms in the cognitive and subjective effects of smoking. Neuropsychopharmacology 2009;34:257-65.
71. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry 2004;61:905-12. (Pubitemid 39181080)
72. Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med 2005;165:1600-5. (Pubitemid 41124153)
73. Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Wallace CL, Dawes MA, et al. Effects of acute topiramate dosing on methamphetamine-induced subjective mood. Int J Neuropsychopharmacol 2007;10:85-98. (Pubitemid 46122755)
74. Kalivas PW, Lalumiere RT, Knackstedt L, Shen H. Glutamate transmission in addiction. Neuropharmacology 2009;56(Suppl):169-73.
75. Kaminski RM, Banerjee M, Rogawski MA. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 2004;46:1097-104. (Pubitemid 38529933)
76. Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004;75:233-40. (Pubitemid 38993293)
77. Kampman KM, Pettinati HM, Lynch KG, Xie H, Dackis C, Oslin DW, et al. Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence. Addict Behav 2009;34:581-6.
78. Kampman KM, Dackis C, Pettinati HM, Lynch KG, Sparkman T, O'Brien CP. A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence. Addict Behav 2011;36:217-21.
79. Kau KS, Madayag A, Mantsch JR, Grier MD, Abdulhameed O, Baker DA. Blunted cystine-glutamate antiporter function in the nucleus accumbens promotes cocaine-induced drug seeking. Neuroscience 2008;155:530-7.
80. Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM. Review of topiramate: an antiepileptic for the treatment of alcohol dependence. Curr Drug Abuse Rev 2009;2:135-42.
81. Kennedy WK, Leloux M, Kutscher EC, Price PL, Morstad AE, Carnahan RM. Acamprosate. Expert Opin Drug Metab Toxicol 2010;6:363-80.
82. Khazaal Y, Zullino DF. Topiramate in the treatment of compulsive sexual behavior: case report. BMC Psychiatry 2006;6:22.
83. Khazaal Y, Cornuz J, Bilancioni R, Zullino DF. Topiramate for smoking cessation. Psychiatry Clin Neurosci 2006;60:384-8. (Pubitemid 43736406)
84. Kheirabadi GR, Ranjkesh M, Maracy MR, Salehi M. Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients. Addiction 2008;103:1495-9.
85. Kiefer F, Mann K. Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy. Curr Pharm Des 2010;16:2098-102.
86. Knackstedt LA, Kalivas PW. Glutamate and reinstatement. Curr Opin Pharmacol 2009;9:59-64.
87. Knackstedt LA, Larowe S, Mardikian P, Malcolm R, Upadhyaya H, Hedden S, et al. The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biol Psychiatry 2009;65:841-5.
88. Knackstedt LA, Melendez RI, Kalivas PW. Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biol Psychiatry 2010;67:81-4.
89. Komanduri R. Two cases of alcohol craving curbed by topiramate. J Clin Psychiatry 2003;64:612. (Pubitemid 36618296)
90. Koob GF, Kenneth Lloyd G, Mason BJ. Development of pharmacotherapies for drug addiction: a Rosetta Stone approach. Nat Rev Drug Discov 2009;8:500-15.
91. Kranzler HR, Gage A. Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials. Am J Addict 2008;17:70-6. (Pubitemid 351156993)
92. Krupitsky EM, Neznanova O, Masalov D, Burakov AM, Didenko T, Romanova T, et al. Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am J Psychiatry 2007a;164:519-23. (Pubitemid 46513168)
93. Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY, Grinenko AA, Pittman B, et al. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res 2007b;31:604-11. (Pubitemid 46434897)
94. Laaksonen E, Koski-Jannes A, Salaspuro M, Ahtinen H, Alho H. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol 2008;43:53-61.
95. Landmark CJ. Targets for antiepileptic drugs in the synapse. Med Sci Monit 2007;13:RA1-7. (Pubitemid 46045538)
96. LaRowe SD, Mardikian P, Malcolm R, Myrick H, Kalivas PW, McFarland K, et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict 2006;15:105-10. (Pubitemid 43207196)
97. LaRowe SD, Myrick H, Hedden S, Mardikian P, Saladin M, McRae A, et al. Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry 2007;164:1115-7. (Pubitemid 47121401)
98. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 1986;27:490-7. (Pubitemid 16026042)
99. Lee JL, Gardner RJ, Butler VJ, Everitt BJ. D-cycloserine potentiates the reconsolidation of cocaine-associated memories. Learn Mem 2009;16:82-5.
100. Lees G, Leach MJ. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex. Brain Res 1993;612:190-9. (Pubitemid 23167279)
101. Lejoyeux M, Lehert P. Alcohol-use disorders and depression: results from individual patient data meta-analysis of the acamprosate-controlled studies. Alcohol Alcohol 2011;46:61-7.
102. Lhuintre JP, Daoust M, Moore ND, Chretien P, Saligaut C, Tran G, et al. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1985;1(8436):1014-6. (Pubitemid 15083618)
103. Lingamaneni R, Hemmings Jr HC. Effects of anticonvulsants on veratridine- and KCl-evoked glutamate release from rat cortical synaptosomes. Neurosci Lett 1999;276:127-30. (Pubitemid 29525506)
104. LoCastro JS, Youngblood M, Cisler RA, Mattson ME, Zweben A, Anton RF, et al. Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study. J Stud Alcohol Drugs 2009;70:186-96.
105. Ma JZ, Ait-Daoud N, Johnson BA. Topiramate reduces the harm of excessive drinking: implications for public health and primary care. Addiction 2006;101:1561-8. (Pubitemid 44527187)
106. Madamba SG, Schweitzer P, Zieglgänsberger W, Siggins GR. Acamprosate (calcium acetylhomotaurinate) enhances the N-methyl-D-aspartate component of excitatory neurotransmission in rat hippocampal CA1 neurons in vitro. Alcohol Clin Exp Res 1996;20:651-8.
107. Madayag A, Lobner D, Kau KS, Mantsch JR, Abdulhameed O, Hearing M, et al. Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine. J Neurosci 2007;27:13968-76. (Pubitemid 351377873)
108. Malcolm R, Swayngim K, Donovan JL, DeVane CL, Elkashef A, Chiang N, et al. Modafinil and cocaine interactions. Am J Drug Alcohol Abuse 2006;32:577-87. (Pubitemid 44870996)
109. Malcolm R, Myrick LH, Veatch LM, Boyle E, Randall PK. Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin. J Clin Sleep Med 2007;3:24-32. (Pubitemid 46761005)
110. Malliarakis KD, Lucey P. Social determinates of health: focus on substance use and abuse. Nurs Econ 2007;25:368-70.
111. Maneuf YP, McKnight AT. Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br J Pharmacol 2001;134:237-40. (Pubitemid 32989119)
112. 3H]-glutamate from the caudal trigeminal nucleus of the streptozotocin-treated rat. Br J Pharmacol 2004;141:574-9.
113. Mann K, Kiefer F, Spanagel R, Littleton J. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 2008;32:1105-10.
114. Mardikian PN, Larowe SD, Hedden S, Kalivas PW, Malcolm RJ. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:389-94. (Pubitemid 46209420)
115. Margolin A, Avants SK, DePhilippis D, Kosten TR. A preliminary investigation of lamotrigine for cocaine abuse in HIV-seropositive patients. Am J Drug Alcohol Abuse 1998;24:85-101. (Pubitemid 28101092)
116. Mariani JJ, Rosenthal RN, Tross S, Singh P, Anand OP. A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. Am J Addict 2006;15:76-84. (Pubitemid 43207192)
117. Martinez-Raga J, Sabater A, Perez-Galvez B, Castellano M, Cervera G. Add-on gabapentin in the treatment of opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:599-601. (Pubitemid 38490773)
118. Martinez-Raga J, Knecht C, Cepeda S. Modafinil: a useful medication for cocaine addiction? Review of the evidence from neuropharmacological, experimental and clinical studies. Curr Drug Abuse Rev 2008;1:213-21.
119. Mason BJ, Heyser CJ. Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. CNS Neurol Disord Drug Targets 2010a;9:23-32.
120. Mason BJ, Heyser CJ. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. Expert Opin Drug Saf 2010b;9:177-88.
121. Mason BJ, Lehert P. The effects of current subsyndromal psychiatric symptoms or past psychopathology on alcohol dependence treatment outcomes and acamprosate efficacy. Am J Addict 2010;19:147-54.
122. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res 2006;40:383-93. (Pubitemid 43816589)
123. Mason BJ, Light JM, Williams LD, Drobes DJ. Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict Biol 2009;14:73-83.
124. McBean GJ. Cerebral cystine uptake: a tale of two transporters. Trends Pharmacol Sci 2002;23:299-302. (Pubitemid 34765619)
125. Mcgeehan AJ, Olive MF. The anti-relapse compound acamprosate inhibits the development of a conditioned place preference to ethanol and cocaine but not morphine. Br J Pharmacol 2003;138:9-12. (Pubitemid 36194197)
126. Mcgeehan AJ, Olive MF. Attenuation of cocaine-induced reinstatement of cocaine conditioned place preference by acamprosate. Behav Pharmacol 2006;17:363-7. (Pubitemid 44258985)
127. Melendez RI, Vuthiganon J, Kalivas PW. Regulation of extracellular glutamate in the prefrontal cortex: focus on the cystine glutamate exchanger and group I metabotropic glutamate receptors. J Pharmacol Exp Ther 2005;314:139-47. (Pubitemid 41065025)
128. Michopoulos I, Douzenis A, Christodoulou C, Lykouras L. Topiramate use in alprazolam addiction. World J Biol Psychiatry 2006;7:265-7. (Pubitemid 44650537)
129. Minozzi S, Amato L, Davoli M, Farrell M, Lima Reisser AA, Pani PP, et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev 2008:CD006754.
130. Miranda Jr R, MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res 2008;32:489-97. (Pubitemid 351300992)
131. Montoya ID, Vocci F. Novel medications to treat addictive disorders. Curr Psychiatry Rep 2008;10:392-8.
132. Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci 2005;25:6389-93. (Pubitemid 40962534)
133. Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 2006;101:1451-62. (Pubitemid 44337770)
134. Moussawi K, Kalivas PW. Group II metabotropic glutamate receptors (mGlu2/3) in drug addiction. Eur J Pharmacol 2010;639:115-22.
135. Moussawi K, Pacchioni A, Moran M, Olive MF, Gass JT, Lavin A, et al. N-Acetylcysteine reverses cocaine-induced metaplasticity. Nat Neurosci 2009;12:182-9.
136. Myers KM, Davis M. Mechanisms of fear extinction. Mol Psychiatry 2007;12:120-50. (Pubitemid 46160979)
137. Myers KM, Carlezon Jr WA, Davis M. Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology 2011;36:274-93.
138. Myrick H, Malcolm R, Brady KT. Gabapentin treatment of alcohol withdrawal. Am J Psychiatry 1998;155:1632.
139. Myrick H, Henderson S, Brady KT, Malcolm R. Gabapentin in the treatment of cocaine dependence: a case series. J Clin Psychiatry 2001;62:19-23. (Pubitemid 32154313)
140. Myrick H, Anton R, Voronin K, Wang W, Henderson S. A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin Exp Res 2007;31:221-7. (Pubitemid 46155221)
141. Myrick H, Malcolm R, Randall PK, Boyle E, Anton RF, Becker HC, et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res 2009;33:1582-8.
142. Naassila M, Hammoumi S, Legrand E, Durbin P, Daoust M. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 1998;22:802-9. (Pubitemid 28292462)
143. Nic Dhonnchadha BA, Szalay JJ, Achat-Mendes C, Platt DM, Otto MW, Spealman RD, et al. D-cycloserine deters reacquisition of cocaine self-administration by augmenting extinction learning. Neuropsychopharmacology 2010;35:357-67.
144. Niehaus JL, Cruz-Bermudez ND, Kauer JA. Plasticity of addiction: a mesolimbic dopamine short-circuit? Am J Addict 2009;18:259-71.
145. O'Brien CP. Evidence-based treatments of addiction. Philos Trans R Soc Lond B Biol Sci 2008;363:3277-86.
146. Olive MF. Metabotropic glutamate receptor ligands as potential therapeutics for drug addiction. Curr Drug Abuse Rev 2009;2:83-98.
147. Olive MF. Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction. Eur J Pharmacol 2010;639:47-58.
148. Pavlovic Z. Lamotrigine reduces craving and depressive symptoms in cocaine dependence. J Neuropsychiatry Clin Neurosci 2011;23:E32.
149. Perez de la Mora M, Aguilar-Garcia A, Ramon-Frias T, Ramirez-Ramirez R, Mendez-Franco J, Rambert F, et al. Effects of the vigilance promoting drug modafinil on the synthesis of GABA and glutamate in slices of rat hypothalamus. Neurosci Lett 1999;259:181-5. (Pubitemid 29059614)
150. Popp RL, Lovinger DM. Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur J Pharmacol 2000;394:221-31. (Pubitemid 30195705)
151. Price KL, McRae-Clark AL, Saladin ME, Maria MM, DeSantis SM, Back SE, et al. Dcycloserine and cocaine cue reactivity: preliminary findings. Am J Drug Alcohol Abuse 2009;35:434-8.
152. Putzke J, Spanagel R, Tolle TR, Zieglgansberger W. The novel anti-craving drug acamprosate alters the expression of NMDA1 receptor splice variant mRNAs in the rat brain. J Neural Transm 1996;103:XLV-XLVI.
153. Raby WN. Gabapentin therapy for cocaine cravings. Am J Psychiatry 2000;157:2058-9.
154. Raby WN, Coomaraswamy S. Gabapentin reduces cocaine use among addicts from a community clinic sample. J Clin Psychiatry 2004;65:84-6.
155. Raj YP. Gambling on acamprosate: a case report. J Clin Psychiatry 2010;71:1245-6.
156. Rammes G, Mahal B, Putzke J, Parsons C, Spielmanns P, Pestel E, et al. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 2001;40:749-60. (Pubitemid 32436452)
157. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009;373:2223-33.
158. Reid MS, Palamar J, Raghavan S, Flammino F. Effects of topiramate on cue-induced cigarette craving and the response to a smoked cigarette in briefly abstinent smokers. Psychopharmacology 2007;192:147-58. (Pubitemid 46673896)
159. Reilly MT, Lobo IA, McCracken LM, Borghese CM, Gong D, Horishita T, et al. Effects of acamprosate on neuronal receptors and ion channels expressed in Xenopus oocytes. Alcohol Clin Exp Res 2008;32:188-96.
160. Reis AD, Castro LA, Faria R, Laranjeira R. Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial. Rev Bras Psiquiatr 2008;30:132-5. (Pubitemid 351955879)
161. Reissner KJ, Kalivas PW. Using glutamate homeostasis as a target for treating addictive disorders. Behav Pharmacol 2010;21:514-22.
162. Richardson K, Baillie A, Reid S, Morley K, Teesson M, Sannibale C, et al. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? Addiction 2008;103:953-9. (Pubitemid 351703480)
163. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5:553-64. (Pubitemid 38868551)
164. Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010:CD004332.
165. Ross S, Peselow E. Pharmacotherapy of addictive disorders. Clin Neuropharmacol 2009;32:277-89.
166. Rubio G, Ponce G, Jimenez-Arriero MA, Palomo T, Manzanares J, Ferre F. Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry 2004;37:37-40. (Pubitemid 38230738)
167. Rubio G, Lopez-Munoz F, Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord 2006;8:289-93.
168. Rubio G, Martinez-Gras I, Manzanares J. Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence. J Clin Psychopharmacol 2009;29:584-9.
169. Rustembegovic A, Sofic E, Tahirovic I, Kundurovic Z. A study of gabapentin in the treatment of tonic-clonic seizures of alcohol withdrawal syndrome. Med Arh 2004;58:5-6.
170. Santa Ana EJ, Rounsaville BJ, Frankforter TL, Nich C, Babuscio T, Poling J, et al. D-Cycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: a pilot investigation. Drug Alcohol Depend 2009;104:220-7.
171. Sari Y, Smith KD, Ali PK, Rebec GV. Upregulation of Glt1 attenuates cue-induced reinstatement of cocaine-seeking behavior. J Neurosci 2009;29:9239-43.
172. Schnoll RA, Wileyto EP, Pinto A, Leone F, Gariti P, Siegel S, et al. A placebo-controlled trial of modafinil for nicotine dependence. Drug Alcohol Depend 2008;98:86-93.
173. Shearer J, Darke S, Rodgers C, Slade T, van Beek I, Lewis J, et al. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction 2009;104:224-33.
174. Sheinin A, Shavit S, Benveniste M. Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine. Neuropharmacology 2001;41:151-8.
175. Shen YC. Treatment of inhalant dependence with lamotrigine. Prog Neuropsychopharmacol Biol Psychiatry 2006;31:769-71.
176. Shimoyama M, Shimoyama N, Hori Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain 2000;85:405-14.
177. 3H]glutamate in hippocampal nerve endings. Neuropharmacology 2007;52:598-605.
178. Snyder JL, Bowers TG. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials. Am J Drug Alcohol Abuse 2008;34:449-61.
179. Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev 2009;89:649-705.
180. Spanagel R, Pendyala G, Abarca C, Zghoul T, Sanchis-Segura C, Magnone MC, et al. The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat Med 2005;11:35-42.
181. Tata AL, Kockler DR. Topiramate for binge-eating disorder associated with obesity. Ann Pharmacother 2006;40:1993-7.
182. Teoh H, Fowler LJ, Bowery NG. Effect of lamotrigine on the electrically-evoked release of endogenous amino acids from slices of dorsal horn of the rat spinal cord. Neuropharmacology 1995;34:1273-8.
183. Thanos PK, Bermeo C, Wang GJ, Volkow ND. D-Cycloserine accelerates the extinction of cocaine-induced conditioned place preference in C57BL/c mice. Behav Brain Res 2009;199:345-9.
184. Thavorncharoensap M, Teerawattananon Y, Yothasamut J, Lertpitakpong C, Chaikledkaew U. The economic impact of alcohol consumption: a systematic review. Subst Abuse Treat Prev Policy 2009;4:20.
185. Torregrossa MM, Sanchez H, Taylor JR. D-cycloserine reduces the context specificity of Pavlovian extinction of cocaine cues through actions in the nucleus accumbens. J Neurosci 2010;30:10526-33.
186. Tzschentke TM, Schmidt WJ. Glutamatergic mechanisms in addiction. Mol Psychiatry 2003;8:373-82.
187. Umhau JC, Momenan R, Schwandt ML, Singley E, Lifshitz M, Doty L, et al. Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry 2010;67:1069-77.
188. Uys JD, LaLumiere RT. Glutamate: the new frontier in pharmacotherapy for cocaine addiction. CNS Neurol Disord Drug Targets 2008;7:482-91.
189. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009;301:1148-54.
190. Voris J, Smith NL, Rao SM, Thorne DL, Flowers QJ. Gabapentin for the treatment of ethanol withdrawal. Subst Abus 2003;24:129-32.
191. Vosburg SK, Hart CL, Haney M, Foltin RW. An evaluation of the reinforcing effects of memantine in cocaine-dependent humans. Drug Alcohol Depend 2005;79:257-60.
192. Waldmeier PC, Baumann PA, Wicki P, Feldtrauer JJ, Stierlin C, Schmutz M. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 1995;45:1907-13.
193. Waldmeier PC, Martin P, Stocklin K, Portet C, Schmutz M. Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum. Naunyn Schmiedebergs Arch Pharmacol 1996;354:164-72.
194. Wang SJ, Sihra TS, Gean PW. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltageactivated calcium channel activity. Neuroreport 2001;12:2255-8.
195. Weiss RD, O'Malley SS, Hosking JD, Locastro JS, Swift R. Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study. J Stud Alcohol Drugs 2008;69:878-84.
196. White WD, Crockford D, Patten S, El-Guebaly N. A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation. Nicotine Tob Res 2005;7:809-13.
197. Winther LC, Saleem R, McCance-Katz EF, Rosen MI, Hameedi FA, Pearsall HR, et al. Effects of lamotrigine on behavioral and cardiovascular responses to cocaine in human subjects. Am J Drug Alcohol Abuse 2000;26:47-59.
198. Wisor JP, Eriksson KS. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience 2005;132:1027-34.
199. Xi ZX, Gardner EL. Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Curr Drug Abuse Rev 2008;1:303-27.
200. Zack M, Poulos CX. Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity. J Psychopharmacol 2009;23:660-71.
201. Zahm DS. Pharmacotherapeutic approach to the treatment of addiction: persistent challenges. Mol Med 2010;107:276-80.
202. Zeise ML, Kasparow S, Capogna M, Zieglgänsberger W. Calcium diacetylhomotaurinate (CA-AOTA) decreases the action of excitatory amino acids in the rat neocortex in vitro. Prog Clin Biol Res 1990;351:237-42.
203. Zeise ML, Kasparov S, Capogna M, Zieglgänsberger W. Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur J Pharmacol 1993;231:47-52.